Skip to main content
. Author manuscript; available in PMC: 2013 Aug 7.
Published in final edited form as: Am J Gastroenterol. 2008 Sep 4;103(10):2432–2442. doi: 10.1111/j.1572-0241.2008.02117.x

Table 7.

Improved Drug Profile Scenarios “Would you be willing to take this drug if …”

Celecoxib Aspirin
% Willing to take drug, base case 15.0% 76.0%
Scenario 1: Improved EAC risk (EAC risk eliminated, ▼100%; MI, stroke, GIE risks unchanged) 43.0% 87.0%
Scenario 2: Improved MI risk (MI risk, no increase, ▲0%; EAC; stroke; GIE unchanged) 42.0% –
Scenario 3: Improved MI risk (MI risk eliminated, ▼100%; EAC, GIE risks unchanged) – 86.0%
Scenario 4: Improved stroke risk (Stroke risk, no increase, ▲0%; EAC; MI; GIE unchanged) 29.4% –
Scenario 5: Improved GIE risk (GIE risk, no increase, ▲0%; EAC; MI; stroke unchanged 25.0% 97.0%

EAC = esophageal adenocarcinoma; MI = myocardial infarction; GIE = gastrointestinal event, which includes ulcer or gastrointestinal bleeding; ▼ = decrease; ▲ = increase.